Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.

ABSTRACT:

Background

Immunocompromised individuals are at high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent severe or fatal coronavirus disease 2019 (COVID-19), yet they have suboptimal responses to mRNA and inactivated COVID-19 vaccines. The efficacy of tixagevimab-cilgavimab in reducing symptomatic SARS-CoV-2 infection was demonstrated in phase III clinical trials. Nevertheless, real-world data on the effectiveness and safety of tixagevimab-cilgavimab remain limited.

Objective

The aim was to evaluate the effectiveness and safety of tixagevimab-cilgavimab among immunocompromised individuals.

Methods

Adults who were immunocompromised or receiving immunosuppressive therapies were included in this target trial emulation using terri

SUBMITTER: Yan VKC 

PROVIDER: S-EPMC11399184 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature